A multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders. What if, in people with blinding retinal disorders, one could simply introduce into the retina healthy photoreceptor cells derived in a dish from
Interdisciplinary team of researchers from UMass Amherst and UMass Chan Medical School maps the cellular production of protein and discovers how to boost its output In a major new development in the quest to develop better gene therapies with which to treat a host of diseases, researchers at the University of Massachusetts Amherst and UMass
CNS relapse is still a common cause of treatment failure in R/R B-ALL, although chemotherapy, cranial irradiation, and allo-HSCT are all modalities that can be incorporated into the management of CNSL. In the present study, published on Blood by a team of Xuzhou Medical University, was reported the efficacy, toxicity, and clinical feasibility of CD19-specific
Hannover Medical School doctors successfully treat three-year-old girl / Publication in “Nature Cardiovascular Research“ Clinical researchers at Hannover Medical School (MHH) have succeeded for the first time worldwide in stopping the usually fatal course of the disease in severe pulmonary hypertension thanks to a novel therapeutic approach. A three-year-old girl suffering from so-called pulmonary arterial
Given recent progress in cell therapy research, it is clear that the engineering disciplines outlined in this Review will play an increasing role in the creation of new product pipelines with improved safety, efficacy and accessibility for patients. Recent scientific advances have not only demonstrated the potential impact of technologiesdeveloped by each of these fields,
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug. The modified cells are safer, more potent and more active against solid tumors in mice. A cancer treatment that uses a patient’s own genetically modified immune cells to attack cancer cells is safer and more effective when it can be
Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord. Their research, published today in Clinical and Translational Medicine, demonstrates that AZD1236, a drug developed by AstraZeneca, can significantly reduce “secondary damage” caused by the body’s response to spinal
Researchers at Karolinska Institutet, Technical University of Munich (TUM) in Germany and AstraZeneca, among others, have identified a new type of cell therapy with the potential to heal injuries to the heart after a heart attack. The preclinical study, published in the journal Nature Cell Biology, shows that so-called ventricular progenitor cells can stimulate the heart’s
Fifth generation polyrotaxane (PRX) carriers can effectively deliver CRISPR-Cas9 ribonucleoproteins (RNPs) The PRX carrier can cross the cell membrane, avoid endosomal action, and release Cas9 RNP for entry into the nucleusImage courtesy: Kumamoto University, The carriers, aminated polyrotaxanes, can flexibly and reversibly bind with Cas9 ribonucleoprotein and protect it from intracellular endosomal degradation CRISPR-Cas9 is
Chimeric antigen receptor T-cell therapy, or CAR T, has made a big impact on the treatment of certain blood cancers, allowing patients with relapsed/refractory disease to live longer, healthier lives. But in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor
